Overview
- The peer-reviewed findings were published online on Sept. 26, 2025, in Advanced Science.
- As a proof of concept, the model reproduced flucloxacillin-triggered liver injury in HLA-B*57:01 carriers, including T cell activation, cytokine release, and hepatocyte damage.
- Researchers aim to close a known gap in preclinical testing where standard assays and animal models miss idiosyncratic, immune-mediated liver injury.
- The CuSTOM Accelerator is advancing automation and high-throughput screening to test larger, genetically diverse donor cohorts.
- The project involved collaborators from Genentech and Molecular Devices, with funding from Roche, Danaher, and the Farmer Family Foundation.